Raffaele Colombo: Trastuzumab rezetecan in patients with HER2-mutant NSCLC
Raffaele Colombo shared a post on X about a recent paper by Shun Lu et al. published in STTT, commenting:
“Phase 1/2 study of SHR-A1811 (trastuzumab rezetecan) in patients with HER2-mutant NSCLC published on Signal Transduction and Targeted Therapy (STTT). .
At 4.8 mg/kg (RP2D):
- ORR=41.9%
- DoR=13.7 months
- PFS=8.4 months
- ILD=11.6% (low grade)
A lot of similarities to T-DXd in DESTINY-Lung02.
Trastuzumab deruxtecan (T-DXd) vs trastuzumab rezetecan (SHR-A1811):
- = Identical mAb (trastuzumab)
- = Identical linker (MC-GGFG)
- ~ Slightly different payload (DXd vs SHR’9265)
- ~ Slightly different DAR (8 vs 6).”
Authors: Ziming Li, Zhengbo Song, Wei Hong, Nong Yang, Yongsheng Wang, Hong Jian, Zibin Liang, Sheng Hu, Min Peng, Yan Yu, Yan Wang, Zicong Jiao, Kaijing Zhao, Ke Song, You Li, Wei Shi and Shun Lu.
Source: Raffaele Colombo/X
Raffaele Colombo, a leading figure in the pharmaceutical industry is the Associate Director of Medicinal Chemistry at Zymeworks Inc..
His leadership and scientific acumen drive the discovery and optimization of novel drug candidates and advancing the treatment landscape for various diseases.